NASDAQ · PYPD

PolyPid Ltd.

$3.90 -$0.34 (-8.02%) 1D After hours

Key Metrics

$81.30M
Market cap
P/E · TTM
Revenue · TTM
−$34.17M
Net income
EPS · TTM $-24.04
Dividend yield
Free cash flow −$28.09M
Beta · 1Y 1.05
EBITDA · TTM −$31.51M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 21
    From its Jul 6 high, the share price fell 33%.

    Peak close $5.58 on Jul 6; trough close $3.74 on Jul 21. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -33%
  • Jul 21
    The stock moved -27.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 21
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 6
    The stock moved +11.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$81.30M
Enterprise value$76.52M
Shares outstanding19.2M
52-wk range$3.06 – $5.73
Avg volume · 20D46.3K
Net cash $4.78M
Book value / share$7.72
ExchangeNASDAQ
About PolyPid Ltd.
IPO dateJun 26, 2020
Employees75

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -366.3% · -532.4%

Financial Health

Current ratio1.97
Quick ratio
Debt / equity0.15
Debt / EBITDA -0.05
Net cash $4.78M
Working capital$7.49M

Cash Flow · TTM

Operating CF −$27.88M
Capex −$210.00K
Free cash flow −$28.09M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings